Alison Sechrest

Alison Sechrest

Associate

Alison Sechrest is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she practices corporate and securities law.

During law school, Alison was a law clerk in the University of California’s Office of the General Counsel in the Health Affairs and Technology Group.

Experience

Alison Sechrest is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she practices corporate and securities law.

During law school, Alison was a law clerk in the University of California’s Office of the General Counsel in the Health Affairs and Technology Group.

Education

J.D., Duke University School of Law, 2022Cum Laude; Staff Editor, Duke Law Journal
M.A., Bioethics and Science Policy, Duke University Graduate School, 2022
B.S., Psychobiology, University of California, Los Angeles, 2018
Magna Cum Laude

Admissions

State Bar of California

Credentials

Education

J.D., Duke University School of Law, 2022Cum Laude; Staff Editor, Duke Law Journal
M.A., Bioethics and Science Policy, Duke University Graduate School, 2022
B.S., Psychobiology, University of California, Los Angeles, 2018
Magna Cum Laude

Admissions

State Bar of California

Corporate

Recent Insights

Client Highlights

On April 8, 2026, Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific antibody-drug conjugates (ADCs) for the treatment of cancer, announced the closing of an oversubscribed $137 million Series B financing. The round was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from the sole Series A investor OrbiMed, as well as new investors including Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and Alexandria Venture Investments. Wilson Sonsini Goodrich & Rosati advised Sidewinder Therapeutics on the transaction.

Learn More

Client Highlights

On March 31, 2026, Ambrosia Biosciences, Inc., a privately held drug discovery company, announced a $100 million oversubscribed Series B preferred stock financing. The round was co-led by new investors Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital. Existing investors BVF Partners and Boulder Ventures also participated, and were joined by additional new investors. Wilson Sonsini Goodrich & Rosati advised Ambrosia Biosciences on the transaction.

Learn More